Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Jan;62(1):125-35.
doi: 10.1007/s00262-012-1319-0. Epub 2012 Jul 31.

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

Surasak Phuphanich  1 , Christopher J Wheeler, Jeremy D Rudnick, Mia Mazer, Hongqian Wang, Miriam A Nuño, Jaime E Richardson, Xuemo Fan, Jianfei Ji, Ray M Chu, James G Bender, Elma S Hawkins, Chirag G Patil, Keith L Black, John S Yu
Affiliations
Clinical Trial

Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma

Surasak Phuphanich et al. Cancer Immunol Immunother. 2013 Jan.

Abstract

Background: This study evaluated the safety and immune responses to an autologous dendritic cell vaccine pulsed with class I peptides from tumor-associated antigens (TAA) expressed on gliomas and overexpressed in their cancer stem cell population (ICT-107).

Methods: TAA epitopes included HER2, TRP-2, gp100, MAGE-1, IL13Rα2, and AIM-2. HLA-A1- and/or HLA-A2-positive patients with glioblastoma (GBM) were eligible. Mononuclear cells from leukapheresis were differentiated into dendritic cells, pulsed with TAA peptides, and administered intradermally three times at two-week intervals.

Results: Twenty-one patients were enrolled with 17 newly diagnosed (ND-GBM) and three recurrent GBM patients and one brainstem glioma. Immune response data on 15 newly diagnosed patients showed 33 % responders. TAA expression by qRT-PCR from fresh-frozen tumor samples showed all patient tumors expressed at least three TAA, with 75 % expressing all six. Correlations of increased PFS and OS with quantitative expression of MAGE1 and AIM-2 were observed, and a trend for longer survival was observed with gp100 and HER2 antigens. Target antigens gp100, HER1, and IL13Rα2 were downregulated in recurrent tumors from 4 HLA-A2+ patients. A decrease in or absence of CD133 expression was seen in five patients who underwent a second resection. At a median follow-up of 40.1 months, six of 16 ND-GBM patients showed no evidence of tumor recurrence. Median PFS in newly diagnosed patients was 16.9 months, and median OS was 38.4 months.

Conclusions: Expression of four ICT-107 targeted antigens in the pre-vaccine tumors correlated with prolonged overall survival and PFS in ND-GBM patients. The goal of targeting tumor antigens highly expressed on glioblastoma cancer stem cells is supported by the observation of decreased or absent CD133 expression in the recurrent areas of gadolinium-enhanced tumors.

PubMed Disclaimer

Conflict of interest statement

JSY and JGB were salaried employees of and owned stock in ImmunoCellular Therapeutics. ESH and KLB were consultants for and owned stock in ImmunoCellular Therapeutics. All other authors declare that they have no conflicts of interest.

Figures

Fig. 1
Fig. 1
Diagram of treatment schedule and events
Fig. 2
Fig. 2
a Correlation of quantitative antigen expression on primary tumor from ND patients with progression-free survival (n = 13). Logarithmic plots of antigen expression determined by qRT-PCR (see “Patients and methods”) showed correlations of increasing antigen expression with longer progression-free survival times (PFS). Antigen expression was measured from fresh-frozen samples and calculated relative to GAPDH. b Correlation of quantitative antigen expression on primary tumor from ND patients with overall survival (n = 13). Logarithmic plots of antigen expression determined by qRTPCR (see “Patients and methods”) showed correlations of increasing antigen expression with longer overall survival time (OS)
Fig. 3
Fig. 3
Downregulation of target antigens in recurrent tumors from HLA-A2+ patients. Antigen expression was from FFPE samples and calculated relative to GADPH. Significant downregulation post-vaccine of A2 epitopes gp100, HER2, and IL13Rα2 relative to upregulations was observed (p = 0.023, Fisher’s exact test). Downregulation of the HLA-A1 antigen, AIM2, was not significant (p = 0.21) in these patients
Fig. 4
Fig. 4
CD133 expression by RT-PCR in primary tumor and samples from subsequent surgeries from newly diagnosed and recurrent patients. Expression is from FFPE samples and calculated relative to GADPH as described in “Patients and methods”. The sample for Patient 19 was negative for tumor
Fig. 5
Fig. 5
a Kaplan–Meier estimates of progression-free survival for newly diagnosed patients (n = 16). Dotted lines illustrate the 95 % confidence intervals, and hash marks denote censored patients. b Kaplan–Meier estimates of overall survival for newly diagnosed patients (n = 16). Dotted lines illustrate the 95 % confidence intervals, and hash marks denote censored patients
Fig. 6
Fig. 6
Gating strategy for intracellular cytokine analysis in CD8+ cells. Identical gain and gating was employed on all stimulated, unstimulated, pre-, and post-vaccine plots prior to analysis. Representative antigen-stimulated, post-vaccine plots from a IFNγ-responsive patient (#4) are shown
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330. - DOI - PubMed
    1. Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, Pepkowitz S, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68:5955–5964. doi: 10.1158/0008-5472.CAN-07-5973. - DOI - PubMed
    1. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH et al (2010) Gene expression profile correlates with T cell infiltration and survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res - PMC - PubMed
    1. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev. 2008;222:256–276. doi: 10.1111/j.1600-065X.2008.00617.x. - DOI - PubMed
    1. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol. 2003;15:138–147. doi: 10.1016/S0952-7915(03)00015-3. - DOI - PubMed

Publication types

MeSH terms